

Press Release

07 May 2024 10:35:00 CEST

2CUREX AB (PUBL) HAS DECIDED TO APPLY FOR A DELISTING OF ITS SHARES ON NASDAQ FIRST NORTH GROWTH MARKET IN STOCKHOLM – EXPECTED LAST DAY OF TRADING BY END OF JUNE

INSIDE INFORMATION: The Board of Directors of 2cureX AB (publ) (the "Company" or "2cureX") announced on 16 March 2024 an update on the Company's financial situation and current operations as well as the intention to apply for a delisting of 2cureX shares from Nasdaq First North Growth Market in Stockholm. The Board of Directors of 2cureX has resolved to proceed with a formal delisting application. In accordance with good market practise on the Swedish stock market, 2cureX will after three months from the announcement on 16 March 2024 file an official request for delisting to Nasdaq Stockholm AB, which will be made on 17 June 2024. The last day of trading in 2cureX shares is expected to be on 28 June 2024.

Background

2cureX was founded in 2007 and listed at Nasdaq First North Growth Market in 2017. 2cureX has during this period developed, clinically validated and CE IVD certified its 3D functional drug sensitivity test, IndiTreat. However, 2cureX has over the last two years experienced a significant decline in the Company's share price which has significantly affected the possibilities to raise capital. The negative trend has primarily been caused by a failed business strategy (for details see [Interim Report Q4 2023](#)). **Decision to delist the Company's shares on Nasdaq First North Growth Market and Outlook** As a result of the significant decline in the Company's share price the last two years and the current operational status of the Company, the liquidity and trading in the share on Nasdaq First North Growth Market has also significantly decreased. Qualified shareholders[1] in the Company's shares are significantly below the initial listing requirement of 300 qualified shareholders. It has also been concluded that the Company does not meet several of the applicable ongoing listing requirements on Nasdaq First North Growth Market. Furthermore, the Company is still in a severely financial distressed position as announced on 16 March 2024. The Board of Directors believes that the best way of securing future financing and growth of the company will be as an unlisted private company. Therefore, it has decided to apply for a delisting of the Company's shares on Nasdaq First North Growth Market in Stockholm.

The Company is confident that it, as private company, will be able to execute on its revised business plan to develop IndiTreat® as a decentralized offering for individual hospitals.

Delisting procedure and timeline

In accordance with good practice on the Swedish stock market an application for delisting may at the earliest be filed three months after the announcement on 16 March 2024, which is 17 June 2024.

Delisting the Company's shares from trading on Nasdaq First North Growth Market in Stockholm is conditional on the request being approved by Nasdaq Stockholm AB. The Company's shares will continue to be tradable until the last day of trading. The last day of trading is determined by Nasdaq Stockholm AB and is expected to be on 28 June 2024. Following the last day of trading, the Company's share will be removed from trading on Nasdaq First North Growth Market. The Company will publicly announce the submission of the delisting application and subsequently upon receiving Nasdaq Stockholm AB's approval of the delisting and the last day of trading.

There will be no obligation for the Company's shareholders to sell their shares in connection with the delisting process.

Effects on the Company's shareholders

As a result of delisting the Company's shares on Nasdaq First North Growth Market, there will effectively no longer be an active marketplace for trading of the Company's shares. Any future trades in the Company's shares will be "over-the-counter". For this reason, the liquidity of the Company's shares will decrease further. This will also mean that it becomes more difficult to execute transactions in the Company's shares which may require legal assistance. Parties involved in over-the-counter transactions must finance any needed legal assistance themselves. Furthermore, by delisting, the Company will no longer be covered by, among other things, the disclosure obligations of the Market Abuse Regulation (MAR) and the set of rules that apply to companies admitted to trading on Nasdaq First North Growth Market. However, the Company will continue to be covered by, among other things, the rules of the Swedish Companies Act and the Swedish Annual Accounts Act.

There may be changes in a shareholder's tax legal position in relation to the delisting of the shares and current shareholders might not be eligible to hold shares in a Swedish Investment Savings Account (Sw. *Investeringsparkonto*) after the delisting. Shareholders are encouraged to consult expertise in this regard.

[1] Shareholders holding shares with a value of at least EUR 500

For more information about 2cureX:

Kenneth Graabek Johansen, Acting Chief Executive Officer & Chief Financial Officer

E-mail: kgj@2curex.com

Telephone: +45 23 49 02 27

www.2curex.com

This information is information that 2cureX is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-05-07 10:35 CEST.

Attachments

2CUREX AB (PUBL) HAS DECIDED TO APPLY FOR A DELISTING OF ITS SHARES ON NASDAQ FIRST NORTH GROWTH MARKET IN STOCKHOLM – EXPECTED LAST DAY OF TRADING BY END OF JUNE